(Q37036939)

17 August 2017

Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme (English)

1 reference

17 August 2017

phase II clinical trial

0 references

0 references

1 reference

1 reference

Vinay K Puduvalli

1

1 reference

17 August 2017

Pierre Giglio

2

1 reference

17 August 2017

Morris D Groves

3

1 reference

17 August 2017

Kenneth R Hess

4

1 reference

17 August 2017

Mark R Gilbert

5

1 reference

17 August 2017

Srikanth Mahankali

6

1 reference

17 August 2017

Edward F Jackson

7

1 reference

17 August 2017

Victor A Levin

8

1 reference

17 August 2017

Charles A Conrad

9

1 reference

17 August 2017

Sigmund H Hsu

10

1 reference

17 August 2017

Howard Colman

11

1 reference

17 August 2017

John F de Groot

12

1 reference

17 August 2017

Melesa G Ritterhouse

13

1 reference

17 August 2017

Sandra E Ictech

14

1 reference

17 August 2017

W K Alfred Yung

15

1 reference

17 August 2017

language of work or name

1 reference

26 February 2008

1 reference

17 August 2017

1 reference

17 August 2017

10

1 reference

17 August 2017

2

1 reference

17 August 2017

216-222

1 reference

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Inhibition of angiogenesis as a therapeutic strategy against brain tumors.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Irinotecan: promising activity in the treatment of malignant glioma.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Thalidomide as an anti-angiogenic agent in relapsed gliomas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Irinotecan-induced colitis

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Irinotecan therapy in adults with recurrent or progressive malignant glioma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Response criteria for phase II studies of supratentorial malignant glioma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2613824

Effect of thalidomide on gastrointestinal toxic effects of irinotecan

4 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18314417

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Irinotecan and thalidomide in metastatic colorectal cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18314417

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18314417

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1215/15228517-2007-060

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

18314417

1 reference